We have read the letter by He and Lv1 and we think the issues raised by the authors are not pertinent to our published work. Specifically, He and Lv raise three issues.
In conclusion, we are convinced that our data support the notion that rapamycin fixes the phenotype of rapamycin-expanded Treg cells both in vitro and in vivo.
- He H, Lv Y. Comment on “Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells” Haematologica 2011;96(9):1357–1365. Haematologica. 2012; 97(5):e16. PubMedhttps://doi.org/10.3324/haematol.2011.061689Google Scholar
- Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006; 177(12):8338-47. PubMedhttps://doi.org/10.4049/jimmunol.177.12.8338Google Scholar
- Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One. 2009; 4(6):e5994. PubMedhttps://doi.org/10.1371/journal.pone.0005994Google Scholar
- Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007; 178(1):320-9. PubMedhttps://doi.org/10.4049/jimmunol.178.1.320Google Scholar